CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website
CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activity at various dose levels in heavily pretreated, advanced solid tumors and lymphomas. Dose escalation in the...
HoneyNaps secures a $11.6 million Series B investment, becoming the No. 1 ranked A.I Sleep Technology Company
HoneyNaps secures $11.6 million in series B funding, propelling its entry into the American medical market. BOSTON, May 24, 2024 /PRNewswire/ -- HoneyNaps, an industry-leading South Korean company in artificial intelligence (AI) sleep data analysis, announced on the 7th that it has closed its series B round of funding, securing $11.6 million. HoneyNaps Solutions...
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates
SUZHOU, China and ROCKVILLE, Md., May 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its four abstracts selected for presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting are now available on...
Busting fear barrier about hormone replacement therapy in new era of menopause management
MANILA, Philippines, May 24, 2024 /PRNewswire/ -- Millions of women around the world continue to suffer unnecessarily from the physical and psychological effects of the menopause because of "mistaken fears" about the risks and benefits of hormone replacement therapy. A world leader in human fertility and women's health has warned that continued...
Antengene To Present One Oral and Four Abstracts at ASCO 2024
Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor (XPO1 Inhibitor) Journal Publication: the first-in-human Phase I dose-escalation study of ATG-017 (ERK1/2 inhibitor) in...
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 24, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the...
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
SUZHOU, China, May 23, 2024 /PRNewswire/ -- On May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal cell carcinoma (R/R mRCC) in an oral presentation at the 27th Annual Meeting of the American Society for Gene & Cell Therapy (ASGCT) in Baltimore. This marked the...
Computex 2024: DeCloak Intelligences Showcases DeCloakVision Multi-Modal AI Privacy-Enhanced Monitoring System Offering the Optimal Balance between Public Safety & Personal Privacy
LAS VEGAS and TAIPEI, May 23, 2024 /PRNewswire/ -- DeCloak Intelligences, a subsidiary of Etron Technology (TPEx: 5351), has won the CES Innovation Award for two consecutive years and its privacy system has also been recognized with the Excellent Manufacturer Innovation Product Award in Taiwan. DeCloakVision, a multi-modal AI privacy-enhanced monitoring system, will be showcased live at Computex 2024....
Vatech Partners with Tygerberg Public Hospital to Improve Dental Care in South Africa
SEOUL, South Korea, May 23, 2024 /PRNewswire/ -- Vatech, a global leader in the dental imaging market, is launching a project to improve dental healthcare in South Africa. Vatech announced today that it has partnered with Tygerberg Hospital in Cape Town, South Africa to donate medical equipment for dental care as well...
Complete Genomics opens U.S. supply chain to genomic sequencing customers through a new manufacturing facility at its San Jose, Calif. headquarters
SAN JOSE, Calif., May 23, 2024 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, recently welcomed vendors, suppliers, customers and employees to a May 17 grand opening celebration of its 10,115 square foot manufacturing facility at its headquarters in San Jose, California. The facility represents the company's inaugural U.S. supply chain, translating into faster delivery times for the company's...
